1 – 30 of 30
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Continued cancer drug approvals in Japan and Europe after market withdrawal in the United States : A comparative study of accelerated approvals
(
- Contribution to journal › Article
-
Mark
Broken beyond repair: self regulation of industry payments to clinicians and hospitals
(
- Contribution to journal › Debate/Note/Editorial
- 2023
-
Mark
Race in clinical trials in Sweden: how regulatory and medical standards in clinical research trump the post-racial discourse
2023) In Sociology of Health & Illness(
- Contribution to journal › Article
-
Mark
Unethical pharmaceutical marketing: a common problem requiring collective responsibility
(
- Contribution to journal › Article
- 2022
-
Mark
The making of a Swedish strategy : How organizational culture shaped the Public Health Agency's pandemic response
(
- Contribution to journal › Article
-
Mark
A “patient-industry complex”? Investigating the financial dependency of UK patient organisations on drug company funding
(
- Contribution to journal › Article
-
Mark
Content and strength of conflict of interest policies at Scandinavian Medical Schools: a cross sectional study
(
- Contribution to journal › Article
- 2021
-
Mark
Pharmaceutical industry self-regulation and non-transparency : country and company level analysis of payments to healthcare professionals in seven European countries
(
- Contribution to journal › Article
-
Mark
Sweden
2021)(
- Chapter in Book/Report/Conference proceeding › Chapter in report
-
Mark
Data Transparency and Pharmaceutical Regulation in Europe : Road to Damascus, or Room without a View?
2021) p.63-94(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
Drug company payments to General Practices in England: cross-sectional and social network analysis
(
- Contribution to journal › Article
-
Mark
Is there evidence for the racialization of pharmaceutical regulation? : Systematic comparison of new drugs approved over five years in the USA and the EU
(
- Contribution to journal › Article
- 2020
-
Mark
Revisiting the pharmaceuticalisation of pandemic influenza using Lukes’ framework of power
(
- Contribution to journal › Article
-
Mark
Sociologiska perspektiv på coronakrisen : Fyra sociologer om samhällets reaktion på covid-19
(
- Contribution to journal › Letter
-
Mark
Ras och genetiska skillnader : Introduktion till avsnittets texter
(
- Contribution to specialist publication or newspaper › Specialist publication article
-
Mark
Under-reported relationship: a comparative study of pharmaceutical industry and patient organisation payment disclosures in the UK (2012-2016)
(
- Contribution to journal › Article
-
Mark
Ras i genetikens tidevarv
(
- Contribution to specialist publication or newspaper › Specialist publication article
-
Mark
Svenska gener? : Om stratifierad precisionsmedicin och genetikens etniska gränsdragningar
(
- Contribution to specialist publication or newspaper › Specialist publication article
-
Mark
Five years of pharmaceutical industry funding of patient organisations in Sweden: cross-sectional study of companies, patient organisations and drugs
2020) In PLoS ONE(
- Contribution to journal › Article
- 2019
-
Mark
Analysis of Pharmaceutical Industry Payments to UK Health Care Organizations in 2015
(
- Contribution to journal › Article
-
Mark
Exposing drug industry funding of UK patient organisations
(
- Contribution to journal › Article
-
Mark
The whistleblowing drama behind Astellas’s suspension from the ABPI
(
- Contribution to journal › Letter
- 2018
-
Mark
Explaining biological depression theories
(
- Contribution to journal › Letter
-
Mark
Let the drugs lead the way! : On the unfolding of a research programme in psychiatry
(
- Contribution to journal › Article
-
Mark
Categorical and anti-categorical approaches to US racial/ethnic groupings: revisiting the National 2009 H1N1 Flu Survey (NHFS)
(
- Contribution to journal › Article
- 2016
-
Mark
Regulating Pharmaceutical Industry Marketing: Development, Enforcement and Outcome of Marketing Rules
(
- Contribution to journal › Article
-
Mark
Unhealthy marketing of pharmaceutical products: An international public health concern
(
- Contribution to journal › Article
-
Mark
Pharmaceutical Industry Off-label Promotion and Self-regulation: A Document Analysis of Off-label Promotion Rulings by the United Kingdom Prescription Medicines Code of Practice Authority 2003-2012.
(
- Contribution to journal › Article
-
Mark
Hail the Tattletale
(
- Contribution to specialist publication or newspaper › Newspaper article
- 2015
-
Mark
Divergence and convergence of commercial and scientific priorities in drug development: the case of Zelmid, the first SSRI antidepressant
(
- Contribution to journal › Article